OR WAIT null SECS
October 01, 2020
Symbiosis has successfully completed a scheduled inspection by MHRA.
Optimus Holding has successfully completed the acquisition of OM Pharma.
Recipharm and BIAL have expanded their long-term supply agreement for the global manufacture and supply of opicapone API.
The technology is a novel, plasmid-free manufacturing system for robust and reproducible manufacture of AAV at scale.
The OneXpress solution is designed to accelerate oral dosage drug development and manufacturing.
pci | bridge makes inventory, production, distribution, and shipping data immediately accessible by integrating the platform with PCI’s other systems, making the data manageable from both sides.
The 60,000-ft2 facility was built using CRB’s ONEsolution project delivery method and was designed to expand GRAM’s large-scale fill/finish capacity.
September 30, 2020
Cellnest will join Fujifilm Irvine Scientific’s PRIME-XV portfolio which consists of xeno-free and chemically defined media for stem cell culture.
The companies are entering into a strategic collaboration for the development and commercialization of CStone’s sugemalimab, a PD-L1 antibody for high-incidence cancer indications, in mainland China.
September 28, 2020
Par Sterile will produce the vaccine for use in Novavax's Phase III clinical trial in the United States, while also providing fill/finish services for commercial distribution in the US.